Home World News EMA Recommends Extension of Therapeutic Indications for Retifanlimab World News EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 500 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Checking in on our Mental Health May 14, 2021 Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML September 14, 2026 Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in... March 17, 2026 Ahead of a Key Meeting of EU Health Ministers, ESMO Calls... June 14, 2026 Load more HOT NEWS Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients... News digest – dinosaur bone cancer, YouTube junk food ad ban... FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for... Withdrawal of the Application to Change the EMA Marketing Authorisation for...
